Clinical trials: Moderate-to-severe Psoriasis
Psoriasis
A Study to Assess the Efficacy and Safety of XP23829 in Subjects With Moderate-to-Severe Chronic Plaque-Type Psoriasis
The study objectives are the following: 1. To evaluate the efficacy of 3 doses of XP23829 compared to placebo for the treatment of moderate-to-severe chronic plaque-type psoriasis. 2.
- Trial name
- NCT02173301
- Testing
- XP23829 400 mg QD, XP 23829 800 mg QD, XP23829 400 mg BID
- Where
- 31 sites in United States
- Volunteers
- 200 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Psoriasis
An Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea
The purpose of this study is to investigate the experimental medication BMS-986165 compared to placebo in participants with moderate to severe plaque psoriasis in mainland China, Taiwan, and South Korea
- Trial name
- POETYK-PSO-3 (NCT04167462)
- Testing
- BMS-986165
- Where
- 34 sites in China, South Korea and 1 more
- Volunteers
- 220 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis
Effects of Desoximetasone Spray 0.25% in Patients With Moderate to Severe Plaque Psoriasis
The objective of this study is to demonstrate that desoximetasone 0.25% topical spray is effective for the treatment of patients with moderate to severe plaque psoriasis.
- Trial name
- NCT01206660
- Testing
- Desoximetasone Spray 0.25%
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Psoriasis
Single Rising Dose Study of BI 655066 in Patients With Moderate and Severe Psoriasis
Safety, tolerability and efficacy of BI 655066 in male and female patients with moderate to severe psoriasis.
- Trial name
- NCT01577550
- Testing
- BI 655066 (very high i.v. dose), BI 655066 (high s.c. dose), BI 655066 (low i.v. dose)
- Where
- 9 sites in United States, Germany and 1 more
- Volunteers
- 39 people
- Sponsor
- AbbVie
Plaque Psoriasis
A Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy
The main aim of this study is to assess whether secukinumab treatment retention over 12 months in adult patients with moderate-to-severe plaque PsO receiving secukinumab in combination with a GLP-1 RA is non-inferior to that in…
- Trial name
- STAY SEC PsO (NCT07881783)
- Volunteers
- 3,718 people
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
Efficacy, Safety, and Immunogenicity of AVT02 With Moderate-to-Severe Chronic Plaque Psoriasis
Safety and Efficacy study of AVT02 (Alvotech Biosimilar to Adalimumab), in patients with moderate to severe plaque psoriasis.
- Trial name
- NCT03849404
- Testing
- Adalimumab
- Where
- 20 sites in Estonia, Georgia and 2 more
- Volunteers
- 413 people
- Sponsor
- Alvotech Swiss AG
Psoriasis
Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis
The goal of this trial is to assess whether the efficacy of CMAB015 is similar to that of Secukinumab in patients with moderate-severe chronic plaque psoriasis.
- Trial name
- NCT06398652
- Testing
- CMAB015, Secukinumab
- Where
- China
- Volunteers
- 336 people
- Sponsor
- Taizhou Mabtech Pharmaceutical Co.,Ltd
Psoriasis
Study to Assess the Change in Disease State When Subcutaneous Risankizumab Injection is Given to Adult Participants With Psoriasis in Taiwan
Psoriasis (PsO) is a chronic, disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques and is associated with high burden of illness that results in a negative impact on long-term health…
- Trial name
- NCT04818385
- Where
- 8 sites in Taiwan
- Volunteers
- 240 people
- Sponsor
- AbbVie
Psoriasis of Scalp, Psoriasis Vulgaris
Apremilast Treatment for Pruritus and Quality of Life in Scalp Psoriasis
A phase 4 multicenter, randomized, placebo-controlled Study evaluating the Effect of Apremilast on Pruritus and Quality of Life of Patients with moderate-to-severe Scalp Psoriasis
- Trial name
- APRESCALP (NCT03553433)
- Testing
- Apremilast 30mg
- Where
- 4 sites in Switzerland
- Volunteers
- 90 people
- Sponsor
- University of Zurich
Psoriasis Vulgaris
Study Evaluating the Efficacy and Safety of Triptergium Wilfordii and Acitretin in Psoriasis Vulgaris - CHINA201002016-2
The purpose of this study is to determine whether Triptergium wilfordii, and Acitretin are effective and safe in the treatment of patient of moderate to severe psoriasis vulgaris.
- Trial name
- NCT01443338
- Testing
- Triptergium Wilfordii, Acitretin
- Where
- China
- Volunteers
- 720 people
- Sponsor
- Ministry of Health, China
Psoriasis
A Study of Efalizumab in Participants With Moderate to Severe Chronic Psoriasis Who Have Failed, Have a Contraindication to, or Are Intolerant of Other Systemic Therapies
This is a Phase IIIb/IV, open label, multicentre study of efalizumab (anti cluster of differentiation [CD] 11a recombinant human monoclonal antibody) in participants with moderate to severe plaque psoriasis who have failed to…
- Trial name
- NCT00249808
- Testing
- Efalizumab - anti-CD11a recombinant human monoclonal antibody
- Where
- United Kingdom
- Volunteers
- 1,266 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Chronic Plaque Psoriasis
A Study to Evaluate the Long-term Safety, Tolerability and Efficacy of Bimekizumab in Patients With Chronic Plaque Psoriasis
This is a multicenter extension study to assess the long-term safety, tolerability and efficacy of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis
- Trial name
- BE ABLE 2 (NCT03010527)
- Testing
- Bimekizumab
- Where
- 36 sites in United States, Canada and 4 more
- Volunteers
- 217 people
- Sponsor
- UCB Biopharma SRL
Psoriasis
Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
The purpose of the study is to assess the safety and efficacy of ABT-874 in the treatment of moderate to severe chronic plaque psoriasis.
- Trial name
- NCT00292396
- Testing
- Anti IL-12 monoclonal antibody/ABT-874
- Where
- 24 sites in United States, Canada
- Volunteers
- 180 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Moderate to Severe Plaque Psoriasis
Investigate Effect of Secukinumab on the PK of Midazolam in Patients With Mod to Sev Plaque Psoriasis
To determine whether secukinumab can alter the activity of cytochrome P450 (CYP) 3A4 using midazolam as probe substrate in patients with moderate-to-severe plaque psoriasis.
- Trial name
- NCT02607774
- Testing
- Midazolam, AIN457
- Where
- 8 sites in United States
- Volunteers
- 25 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis
A One-Year Study To Evaluate The Effects And Safety Of CP-690,550 In Patients With Moderate To Severe Chronic Plaque Psoriasis
The main objective of this study is to compare the effects of CP-690,550 with the effects of placebo in patients being treated for moderate to severe chronic plaque psoriasis.
- Trial name
- NCT01276639
- Testing
- CP-690,550
- Where
- 74 sites in United States, Canada and 9 more
- Volunteers
- 901 people
- Sponsor
- Pfizer
Psoriasis
A Study in Participants With Moderate to Severe Psoriasis (UNCOVER-3)
This study will assess the safety and efficacy of ixekizumab (LY2439821), compared to etanercept and placebo in participants with moderate to severe chronic plaque psoriasis.
- Trial name
- UNCOVER-3 (NCT01646177)
- Testing
- 50 mg etanercept, 80 mg ixekizumab
- Where
- 101 sites in United States, Argentina and 8 more
- Volunteers
- 1,346 people
- Sponsor
- Eli Lilly and Company
Plaque-type Psoriasis
AIN457 Regimen Finding Extension Study in Participants With Moderate to Severe Psoriasis
The purpose of this study was to provide long term clinical data for the compound for the treatment of the indication of moderate to severe chronic plaque-type psoriasis.
- Trial name
- NCT01132612
- Testing
- AIN457
- Where
- 57 sites in United States, France and 5 more
- Volunteers
- 275 people
- Sponsor
- Novartis Pharmaceuticals
Psoriasis Chronic, Liver Fibrosis
An Observational Cohort Study Evaluating Fatty Liver Disease and Liver Fibrosis in Moderate to Severe Psoriasis
Main objectives and outcome measures. 1. Establish prevalence of and factors contributing to fatty liver disease and liver fibrosis in patients with psoriasis. Fatty liver disease diagnosed via ultrasound.
- Conditions
- Psoriasis Chronic, Liver Fibrosis, Fatty Liver, Non-alcoholic Fatty Liver Disease
- Trial name
- CORE (NCT02174367)
- Testing
- Transient elastography
- Where
- United Kingdom
- Volunteers
- 400 people
- Sponsor
- King's College London
Psoriasis
A Double-blind, Placebo-controlled, Randomized, Parallel-group Study to Evaluate the Activity of Oral AB1010 in Adults Patients With Moderate to Severe Chronic Plaque Psoriasis
A double-blind, placebo-controlled, randomized, parallel-group study to evaluate the activity of oral AB1010 in adults patients with moderate to severe chronic plaque psoriasis
- Trial name
- NCT01045577
- Testing
- Masitinib
- Volunteers
- 25 people
- Sponsor
- AB Science
Plaque Psoriasis
Characteristics of Patients Treated With Secukinumab for Moderate to Severe Plaque Psoriasis
This study was a non-interventional, retrospective study collecting data from hospital medical records. Approximately 200 adult patients with moderate to severe plaque psoriasis who were treated with secukinumab from hospitals in…
- Trial name
- NCT05650060
- Testing
- Secukinumab
- Where
- Thailand
- Volunteers
- 163 people
- Sponsor
- Novartis Pharmaceuticals